Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase

Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown o...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Takeshi, Ohguchi, Hiroto, Oda, Asuka, Nakao, Michiyasu, Teramachi, Jumpei, Hiasa, Masahiro, Sumitani, Ryohei, Oura, Masahiro, Sogabe, Kimiko, Maruhashi, Tomoko, Takahashi, Mamiko, Fujii, Shiro, Nakamura, Shingen, Miki, Hirokazu, Kagawa, Kumiko, Ozaki, Shuji, Sano, Shigeki, Hideshima, Teru, Abe, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036510/
https://www.ncbi.nlm.nih.gov/pubmed/36129197
http://dx.doi.org/10.1182/bloodadvances.2022007155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036510/
https://www.ncbi.nlm.nih.gov/pubmed/36129197
http://dx.doi.org/10.1182/bloodadvances.2022007155

Ejemplares similares